A rare clinical presentation of COVID 19: opsoclonus-myoclonus ataxia syndrome

Adalet Altunsoy,Nizamettin Kemirtlek,Halime Araz,Ebru Bilge Dirik,Esragül Akıncı
DOI: https://doi.org/10.3855/jidc.17927
2024-03-15
The Journal of Infection in Developing Countries
Abstract:Introduction: Coronavirus disease 2019 (COVID-19) can have symptoms like many neurological diseases, and one of the rare forms of these presentations is opsoclonus-myoclonus ataxia syndrome (OMAS). The pathogenesis of OMAS in adults has not been clearly elucidated and OMAS can be fatal. Case presentation: We present a 71-year-old male patient who was admitted to the emergency department with complaints of involuntary tremor-like movements in his hands, feet and mouth, and speech impediment for three days, and was followed up with COVID-19. The patient was diagnosed with OMAS and clonazepam treatment was started. He died three days later due to respiratory arrest. Our case is the first case diagnosed with COVID-19-associated OMAS in Turkey. Discussion: OMAS has no definitive treatment. Early diagnosis and initiation of corticosteroids and intravenous immunoglobulin (IVIG) therapy, if necessary, can be life-saving. In COVID-19 patients with unexplained clinical findings, awareness of different and rare diseases and a multidisciplinary approach has vital importance.
infectious diseases
What problem does this paper attempt to address?